Global ETD Search

Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.

Results

Showing 1 to 15 of 15 for “"Esketamine"”.

  1. Promoting Patient Safety During Intranasal Esketamine Administration

    … and nursing staff knowledge regarding intranasal esketamine therapy, promote safety of intranasal eskatamine administration at La Frontera, and increase intent to use a formal safety protocol during administration and patient monitoring. Background: Treatment-resistant depression affects nearly …

    arizona-thes Repository record for Promoting Patient Safety During Intranasal Esketamine Administration (opens in a new tab)

  2. Esketamine Provider Education at an Outpatient Psychiatry Clinic

    … indications, safety, and monitoring protocols of esketamine and evaluate their confidence and intention to use esketamine in practice.Background: Major Depressive Disorder is one of the most common and devastating mental health illnesses that negatively affects people worldwide. It is associated …

    arizona-thes Repository record for Esketamine Provider Education at an Outpatient Psychiatry Clinic (opens in a new tab)

  3. A Presentation of Evidence and Effectiveness of Esketamine Treatments to Psychiatric Providers

    … intended to increase providers’ knowledge about esketamine and its effectiveness in combatting treatment-resistant depression (TRD) by presenting current research and discussing findings. We also aimed to assess providers’ attitudes towards esketamine and their attitudes toward evidence-based …

    arizona-thes Repository record for A Presentation of Evidence and Effectiveness of Esketamine Treatments to Psychiatric Providers (opens in a new tab)

  4. Improving Clinician Knowledge and Confidence in Esketamine-Assisted Psychotherapy: A Quality Improvement Project

    … and motivation to recommend or initiate esketamine-assisted psychotherapy (EAP) through a targeted educational intervention in a large outpatient psychiatric clinic that provides esketamine therapy for treatment-resistant major depressive disorder (TR-MDD). Background: Major depressive …

    arizona-thes Repository record for Improving Clinician Knowledge and Confidence in Esketamine-Assisted Psychotherapy: A Quality Improvement Project (opens in a new tab)

  5. Clinical, Metabolic and Inflammatory Indicators of Esketamine Efficacy for Treatment-Resistant Major Depressive Episodes

    … contribute to inadequate response to treatments. Esketamine has demonstrated promise in TRD, but its biological effects and predictors of response remain poorly understood. This study examined clinical outcomes and metabolic and inflammatory biomarkers in individuals with TRD receiving esketamine. …

    carleton Repository record for Clinical, Metabolic and Inflammatory Indicators of Esketamine Efficacy for Treatment-Resistant Major Depressive Episodes (opens in a new tab)

  6. Development of an Esketamine Treatment Safety Protocol at a Midwestern Outpatient Mental Health Clinic

    … pressure on healthcare systems. Intranasal Esketamine treatment (IET) significantly impacts the severity and rates of depression. Esketamine treatment has led to rapid remission of depressive symptoms within two hours of administration, including the resolution of acute suicidal ideation …

    ku Repository record for Development of an Esketamine Treatment Safety Protocol at a Midwestern Outpatient Mental Health Clinic (opens in a new tab)

  7. Ketamine: a feasible replacement for current major depressive disorder therapies

    … containing the S-enantiomer of ketamine, or esketamine, as an antidepressant therapy. This thesis reviewed the literature on both ketamine and esketamine as antidepressants, with a focus on the two most commonly used routes of administration, intravenous infusion and intranasal …

    bu Repository record for Ketamine: a feasible replacement for current major depressive disorder therapies (opens in a new tab)

  8. Current pharmacotherapies for depression: comparing serotonergic, glutamatergic, and GABA modulating agents

    … which exhibit novel mechanisms of action. Esketamine acts on the glutamatergic system, while brexanolone acts on the GABAergic system. The pharmacological properties of these 3 drugs were compared, through analysis of clinical trials and reviews, in order to determine which mechanism …

    bu Repository record for Current pharmacotherapies for depression: comparing serotonergic, glutamatergic, and GABA modulating agents (opens in a new tab)

  9. Evaluating Ketamine as a Therapeutic Option for Adults with Treatment Resistant Depression: A Systematic Review [paper]

    … treatment resistant depression, adults, esketamine, depression. Findings across studies indicate that ketamine has greater efficacy in treating treatment resistant depression than antidepressant therapy alone. Further research is needed to understand ketamine’s mechanism of action and how …

    texas-state Repository record for Evaluating Ketamine as a Therapeutic Option for Adults with Treatment Resistant Depression: A Systematic Review [paper] (opens in a new tab)

  10. Evaluating Ketamine as a Therapeutic Option for Adults with Treatment Resistant Depression: A Systematic Review [poster]

    … treatment resistant depression, adults, esketamine, depression. Findings across studies indicate that ketamine has greater efficacy in treating treatment resistant depression than antidepressant therapy alone. Further research is needed to understand ketamine’s mechanism of action and how …

    texas-state Repository record for Evaluating Ketamine as a Therapeutic Option for Adults with Treatment Resistant Depression: A Systematic Review [poster] (opens in a new tab)

  11. Offline Reinforcement Learning for Optimizing and Evaluating Early Treatment Initiation Strategies in Treatment-Resistant Depression: A Retrospective Cohort Study Using Administrative Claims Data

    … (antidepressants, antipsychotics, psychotherapy, esketamine, ECT/TMS), yielding 32 combinations per decision point. We formulated sequential decisions as a Markov decision process with a tiered composite outcome burden score constructed from suicide attempt or self-harm (−10), hospitalization, …

    jhu Repository record for Offline Reinforcement Learning for Optimizing and Evaluating Early Treatment Initiation Strategies in Treatment-Resistant Depression: A Retrospective Cohort Study Using Administrative Claims Data (opens in a new tab)

  12. Ketamine vs Sertraline in PTSD Symptom Remission [poster]

    … included examining studies exploring ketamine, esketamine, sertraline, or Zoloft in adult populations that qualified for a diagnosis of Post-Traumatic Stress Disorder. As there were no modern head-to-head studies available for review, each study examined either ketamine (n=4) or sertraline …

    texas-state Repository record for Ketamine vs Sertraline in PTSD Symptom Remission [poster] (opens in a new tab)

  13. PTSD Symptom Reduction with Ketamine Therapy Compared with Traditional Sertraline Therapy: A Systematic Review [paper]

    … included examining studies exploring ketamine, esketamine, sertraline, or Zoloft in adult populations that qualified for a diagnosis of Post-Traumatic Stress Disorder. As there were no modern head-to-head studies available for review, each study examined either ketamine (n=4) or sertraline …

    texas-state Repository record for PTSD Symptom Reduction with Ketamine Therapy Compared with Traditional Sertraline Therapy: A Systematic Review [paper] (opens in a new tab)

  14. Effects of (R,S)-ketamine and (2R,6R)-hydroxynorketamine: a preclinical study

    … of action, the FDA approved (S) ketamine (esketamine, Ketanest, Spravato) for treatment-resistant depression in March 2019. Excitement for a better treatment, however, is lessened by reports indicating that some patients may experience severe side effects like reduced cognitive functioning …

    vcu Repository record for Effects of (R,S)-ketamine and (2R,6R)-hydroxynorketamine: a preclinical study (opens in a new tab)

  15. Intranasales Esketamin zur Behandlung der akuten Depression

    Fragestellung: Reduziert intranasales Esketamin, ergänzend zur Regelbehandlung, schwere depressive Symptome einhergehend mit akuter Suizidalität innerhalb von 24 Stunden und hält ein etwaiger Effekt mittelfristig an? Methodik: Die hier analysierten Daten wurden im Rahmen einer doppelblinden, …

    fu-berlin Repository record for Intranasales Esketamin zur Behandlung der akuten Depression (opens in a new tab)